Section Edited by Ignacio Melero, MD, PhD and Alexandra Snyder Charen, MD
Consisting of predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty.